Latanoprost Sandoz

Latanoprost, the active ingredient in Latanoprost Sandoz, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It increases uveoscleral outflow of aqueous humor, thereby reducing intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latanoprost Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under EU quality standards. The company manages regulatory compliance, secure logistics and reliable batch release for global distribution, and timely delivery to meet client needs.

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma and ocular hypertension.

Open‑angle glaucoma: reduces intra‑ocular pressure and helps preserve visual field. Ocular hypertension: lowers pressure to prevent progression to glaucoma. Secondary open‑angle glaucoma: improves outflow and decreases pressure in secondary forms of the disease.

Latanoprost may cause ocular and peri‑ocular reactions.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash length and thickness. - Darkening of the iris pigment. - Mild eye irritation or foreign‑body sensation. - Blurred vision after instillation. - Dry eye sensation.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis). - Uveitis or intra‑ocular inflammation. - Macular edema, especially in patients with risk factors. - Paradoxical increase in intra‑ocular pressure. - Corneal edema or keratitis. - Endophthalmitis or infectious keratitis.

Before prescribing Latanoprost, clinicians should consider several safety aspects.

Assess intra‑ocular pressure baseline: ensure accurate measurement prior to therapy. Monitor iris color changes: inform patients that permanent darkening may occur. Avoid use in active ocular inflammation: prostaglandin analogs can exacerbate inflammation. Inform about eyelash growth: patients should be aware of cosmetic changes. Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents, requiring attention to combination therapy.

Major Interactions (Avoid): - Concurrent prostaglandin analogs: additive ocular effects may increase irritation. - Ocular anesthetics: combined use may heighten corneal toxicity. - Systemic beta‑blockers: additive intra‑ocular pressure reduction; monitor closely.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may diminish latanoprost efficacy. - Contact lens wear: risk of drug deposition on lenses. - Anticholinergic eye drops: possible reduction in aqueous outflow enhancement.